Collegium Pharmaceutical (COLL) Common Equity (2014 - 2026)

Collegium Pharmaceutical's Common Equity history runs 13 years deep, the most recent figure standing at $312.4 million for Q1 2026.

• On a quarterly basis, Common Equity rose 33.27% year-over-year to $312.4 million in Q1 2026; TTM through Mar 2026 was $312.4 million, a 33.27% increase from a year earlier, with the FY2025 full-year figure at $301.7 million, up 31.83% from the prior year.
• Common Equity improved to $312.4 million in Q1 2026 per COLL's latest filing, from $301.7 million in the prior quarter.
• Across five years, Common Equity topped out at $312.4 million in Q1 2026 and bottomed at $178.9 million in Q3 2023.
• The 5-year median for Common Equity is $216.6 million (2024), against an average of $223.4 million.
• Across the five-year window, Common Equity dropped 21.91% in 2022 and surged 33.27% in 2026, its largest moves.
• Year by year, Common Equity stood at $194.8 million in 2022, then climbed by 0.3% to $195.4 million in 2023, then climbed by 17.1% to $228.8 million in 2024, then jumped by 31.83% to $301.7 million in 2025, then grew by 3.56% to $312.4 million in 2026.
• Per Business Quant, the three latest COLL Common Equity figures stand at $312.4 million (Q1 2026), $301.7 million (Q4 2025), and $274.8 million (Q3 2025).